

- in malabsorption syndromes, 1946t
 significance of, 274
 in thyrotoxicosis, 2294
 treatment of, 275
- Iodides, adverse effects of, 356t, 366, 422
- Iodine, 96e-10
 deficiency of. *See* Iodine deficiency
 excess intake of, 2292
 for goiter, 2301
 metabolism and transport of, 2284–2285, 2285f
 parental supplementation of, 98e-6t
 recommended intake of, 95e-3t, 2285
 tolerable upper intake level of, 96e-9t
 toxicity of, 96e-9t
- Iodine deficiency
 clinical features of, 96e-9t, 2285
 global considerations in, 461, 2285, 2285f
 goiter and, 2301
 hypothyroidism and, 2292
 laboratory evaluation of, 2768–2769
 prevention of, 2292
- Iodine dermatitis, 246e-9
- ¹³¹Iodine-ethiodol, 263e-3t, 263e-6t, 263e-7, 550
- ¹³¹Iodine-MIGB, 2331
- Iodoquinol
 action of, 246e-9
 adverse effects of, 246e-4t, 246e-9
 for amebiasis, 246e-9, 1367t
 contraindications to, 246e-9
 for *D. fragilis* infection, 1409
 pharmacology of, 246e-9
 in pregnancy and lactation, 246e-4t
- Ion absorption, congenital defects in, 268
- Ion channels
 cardiac, 273e-1f, 273e-2, 273e-2f
 neurologic, 444e-2, 444e-2t
- Ion exchangers, for internal radionuclide contamination, 263e-6, 263e-6t
- Ionization, 103e-4
- Ionizing radiation
 AML and, 678
 aplastic anemia and, 663
 breast cancer and, 524
 from cardiac imaging, 270e-7–9
 lung cancer and, 506
 skin damage from, 357
- Iopanoic acid, 727t, 2286t, 2297
- IP-10 (IFN- γ -inducible protein-10), 372e-12t
- IPAF inflammasome, 145e-7
- Ipecac syrup
 adverse effects of chronic use of, 473e-6, 2199
 for internal radionuclide contamination, 263e-6
 for poisoning/drug overdose, 473e-6
- IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked) syndrome, 377e-2, 1949t, 2113, 2347–2348
- IPF1* gene mutations, 431t, 2406
- Ipilimumab
 action of, 102e-5t
 adverse effects of, 359, 380, 499, 607
 indications for, 103e-21t
 for lung cancer, 521
 for melanoma, 103e-22, 498–499
- Ipodate, 2286t, 2297, 2300
- ipr1* gene, 1106
- Ipratropium bromide, 1676, 1705, 2122, 2123f
- Iquitos virus, 1309t
- IRAK1* gene mutations, 2155
- IRAK-4 (interleukin-1 receptor-associated kinase), 950
- IRAK-4 (interleukin-1 receptor-associated kinase) deficiency, 420t
- Iraqi Jewish population, factor XI deficiency in, 736
- Iridectomy, laser, 200
- Iridium exposure, 263e-3t
- Iridocyclitis. *See* Uveitis
- Irinotecan
 action of, 103e-13
 adverse effects of, 40, 103e-10t, 103e-13, 103e-25, 543, 1798
- for carcinoma of unknown primary, 120e-4
 for colorectal cancer, 543
 drug interactions of, 14e-4, 1793
 for Ewing's sarcoma, 119e-4
 for gastric cancer, 535
 genetic variations in response to, 39t
 for lung cancer, 520t, 522
 metabolism of, 34t, 35
 for pancreatic cancer, 557
 for soft tissue sarcoma, 119e-2
- IRIS. *See* Immune reconstitution inflammatory syndrome (IRIS)
- Iritis. *See* Uveitis
- Iron
 absorption of, 625–626, 625f
 accumulation in brain, 2625–2626
 average intake of, 626
 in bone marrow, 81e-8f
 deficiency of, 96e-9t, 98e-5, 192, 461, 463t.
 See also Iron-deficiency anemia;
 Iron-deficient erythropoiesis
 distribution in body, 625, 625t
 excess of. *See* Iron overload
 homeostasis, pathways of, 2515f
 metabolism of, 625–626, 625f
 nutritional balance of, 626
 parenchymal, in liver, 2516
 recommended intake of, 95e-3t, 626
 serum, 393, 397. *See also* Ferritin, serum
 in hypoproliferative anemia, 398, 629–630, 630t
 in iron-deficiency states, 627f
 levels by sex and age, 627–628, 627f
 stores of, 625f, 625t, 626, 627t, 628t, 2517t
 supplements. *See* Iron supplements
 toxicity of. *See* Iron overload
- Iron cycle, 625–626, 625f
- Iron-deficiency anemia, **626**
 causes of, 627, 627t
 clinical features of, 627
 diagnosis of, 627–628, 628t
 differential diagnosis of, 628, 628t
 from gastrointestinal bleeding, 279, 1896–1897
 gastrointestinal cancer and, 535, 541
 global considerations in, 626
 in hookworm infections, 1414
 pathophysiology of, 398
 peripheral blood smear in, 81e-2f, 394f
 stages of, 626–627, 627f
 surgery-related, 1927
 treatment of, 628–629, 629t
- Iron-deficient erythropoiesis, 627, 627f
- Iron dextran, 629
- Iron gluconate, 629
- Iron-hematoxylin stain, 245e-1
- Iron overload
 acute, 626
 chronic, 650
 clinical features of, 96e-9t
 CMR in, 270e-21, 270e-27v
 etiology of, 367e-1t, 2514t, 2516
 in hemochromatosis. *See* Hemochromatosis
 transfusion-related, 138e-5, 631, 639, 667
 treatment of, 639
 in Wilson's disease. *See* Wilson's disease
- Iron poisoning, 473e-11t
- Iron sucrose, 629
- Iron supplements
 adverse effects of, 629
 for iron-deficiency anemia, 628–629, 629t
 oral, 628–629, 629t
 parenteral, 629
- Iron supply studies, 397
- Iron tolerance test, 629
- Irritable bowel syndrome (IBS), **1965**
 approach to the patient, 1967–1968
 clinical features of, **1965**
 abdominal pain/pressure, 105, 106t, 285, 1965
 altered bowel habits, 266, 272t, 1965
 gas and flatulence, 1965–1966
 nausea and vomiting, 259
 upper gastrointestinal, 1966
- diagnostic criteria for, 1965, 1966t, 1967t
 differential diagnosis of, 1968
 incidence of, 266
 pathophysiology of, 1966–1967, 1966t, 1967f
 postinfectious, 797, 855t, 1966–1967
 psychological features in, 1966
 severity spectrum of, 1970t
 treatment of, 272, 1968–1970, 1968t, 1970t
- Irritant contact dermatitis. *See* Contact dermatitis
- Irukandji syndrome, 2739
- IRV (inverse ratio ventilation), 1738, 1742. *See also* Mechanical ventilation
- Isaacs' syndrome, 462e-3, 619
- Ischemia
 acute limb, 1646
 cardiac. *See* Ischemic heart disease
 cerebral, 2559, 2561f. *See also* Ischemic stroke
 intestinal. *See* Intestinal ischemia
- Ischemic cascade, 1777–1778
- Ischemic colitis, 267, 1882f, 1957, 1980
- Ischemic heart disease, **1578**
 angina pectoris in. *See* Angina pectoris
 arrhythmic in, 1580
 asymptomatic (silent), 1580, 1592–1593
 cardiomegaly in, 1580
 cardiomyopathy and, 1580
 in chronic kidney disease, 1816–1817
 diagnosis of
 approach to, 1583f
 cardiac imaging, 1582, 1584f, 1585
 coronary arteriography, 1585–1586
 ECG, 1455–1457, 1455f, 1456f, 1457t, 1582, 1583f
 history, 1580–1581
 laboratory tests, 1582
 physical examination, 1581–1582
 stress testing, 1582, 1583f, 1584f, 1585t
 dyslipidemia and, 1588
 epidemiology of, 1578
 functional classification of, 1439–1440, 1440t, 1501, 1501t, 1581t
 heart failure in, 1579, 1590
 neck pain in, 122
 pathogenesis of, 1578–1580, 1580f. *See also*
 Atherosclerosis; Coronary artery
 disease (CAD)
 prognosis of, 1586
 risk factors for, 1587
 symptomatic, 1580
 treatment of, **1586**
 ACE inhibitors, 1590
 activity adaptation, 1587, 1587t
 aggravating conditions, 1586–1587
 algorithm for, 1591f
 antiplatelet drugs, 1590
 beta blockers, 1588–1590, 1589t
 CABG. *See* Coronary artery bypass grafting
 (CABG)
 calcium channel blockers, 1589–1590, 1589t
 enhanced external counterpulsation, 1592
 explanation and reassurance, 1586
 lipid-lowering therapy, 1588
 nicorandil, 1590
 nitrates, 1588, 1588t
 PCI. *See* Percutaneous coronary
 interventions (PCI), for
 revascularization
 principles, 1441
 ranolazine, 1590
 risk factor management, 1587
 stem cell therapy, 90e-2
 in women, 1588
- Ischemic penumbra, 2560
- Ischemic stroke, **2560**
 after TIA, 2568, 2569t
 clinical features of, 2572, 2572f
 with anterior cerebral artery occlusion, 2573, 2574f
 with anterior choroidal artery occlusion, 2573–2574, 2575f
 with basilar artery occlusion, 2577–2579, 2577–2580f